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Abstract — In the medical practice, there are several 
methods to administer anti-cancer drugs. A commonly used 
method is the intermittent bolus doses (BD) administration 
when the patient receives drug on given days and the therapy 
has rest periods between the injections. The amount of bolus 
doses can be the maximum tolerated dose (MTD) or less. 
Anti-cancer drug can be administered in low doses over 
prolonged periods without extended rest periods which is 
called as low-dose metronomic therapy (LDM). In addition, 
continuous infusion therapy is applicable within clinical 
environment, not yet as a portable device. The major 
disadvantage of these methods is the empiricism associated 
with determining the optimal biologic dose (OBD). In order 
to solve the problem, we have designed discrete-time 
controllers which realize automated optimal treatments.  
Keywords — cancer therapy, protocol, discrete-time 
controller, endostatin, bolus doses, maximum tolerated dose, 
low-dose metronomic therapy, state feedback, setpoint 
control, actual state observer, load estimation 
 
I. INTRODUCTION 
Newest research studies on cancer treatments show the 
importance of specific cancer therapies. The group of 
Targeted Molecular Therapies (TMTs) [1, 2] contains 
several different therapeutic methods; however what they 
have in common is the aim to fight directly against 
specific, identified cancer mechanisms. Antiangiogenic 
therapy [3] is a type of TMT, which acts by inhibiting 
tumor vascularization.  Ceasing the process of 
angiogenesis (new blood vessel formation), tumor growth 
is limited.  
There are several types of antiangiogenic drugs (also 
known as angiogenic inhibitors) like bevacizumab [4], 
angiostatin [5] and endostatin [6]. Delivery of an 
antiangiogenic drug is not a trivial problem since the 
biological effectiveness of the treatment highly depends 
on the applied dosage. Using an empirical method to 
achieve the biological effective dosage, it is not 
guaranteed that the optimal therapy will be found; 
however, using closed-loop control, optimal solution can 
be realized [7, 8]. 
In this paper, we discuss the possible delivery methods 
in cancer therapies which use endostatin. Endostatin is 
able to target neovascular endothelial cells (ECs) and has 
the potential for antiangiogenic and antitumor activities 
[9]. However, it has to be taken into account that 
endostatin has a short half-time [10].  
The paper is organized as follows. In Section II, we 
present the nonlinear model of tumor growth under 
angiogenic inhibition. Section III discusses first the cancer 
protocols in the light of the dosage problem, and then it 
presents the simulation results of the protocol based 
cancer therapies. In Section IV, first the design aspects of 
the discrete time controller with state feedback, setpoint 
control, actual state observer and load estimation are 
summarized, and then the simulation results of the 
discrete-time controller based treatments are evaluated. 
The paper ends with the results and discussion in Section 
V. 
II. THE APPLIED MODEL OF TUMOR GROWTH  
P. Hahnfeldt et al. created a dynamic model for tumor 
growth under antiangiogenic therapy [11]. In a simplified 
version of this model, continuous infusion therapy is taken 
into account [12], where the input (the inhibitor 
administration rate) is equal to the concentration of 
administered inhibitor (serum level of inhibitor) and the 
system is described by the equations: 
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where x1 is the tumor volume (mm3), x2 is the endothelial/ 
vascular volume (mm3) and g is the concentration of the 
administered inhibitor (mg/kg). The model contains the 
following parameters: λ1 is the tumor growth rate (1/day), 
b is the stimulatory capacity of the tumor to the 
vasculature (1/day), d is the endogenous inhibition of 
previously generated vasculature (1/(day·mm2)), e is the 
antiangiogenic effect of the administered inhibitor on the 
tumor vasculature (kg/(day·mg)). 
Parameter values for the considered Lewis lung 
carcinoma and the mice used in the experiment are [11]:  
λ1 = 0.192 1/day, b = 5.85 1/day, d = 0.00873 1/day·mm2. 
The experiment has shown that the most effective 
inhibitor was endostatin; therefore, we have applied this 
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antiangiogenic drug in controller design (the value of 
parameter e for endostatin is eendostatin = 0.66 kg/(day·mg)).  
III. PROTOCOL BASED CANCER THERAPIES 
A. Cancer protocols in the light of the dosage problem 
Methods of drug administration fall into four 
categories: a) bolus doses (BD), b) bolus doses with 
maximum tolerated dose (BD MTD), c) low-dose 
metronomic (LDM) regimen, and d) continuous infusion 
therapy. In this subsection, we draw a distinction between 
these treatments; in addition, we lay emphasis on the 
possible delivery doses in the case of endostatin treatment.  
Using intermittent bolus doses administration, the 
patient receives drug on given days and the therapy has 
rest periods between the injections. The injected amount 
of boluses can be the maximum tolerated dose (MTD) or 
lower dose. The length of the rest periods depends on the 
amount of boluses (e.g. after MTD a longer rest period is 
required). The disadvantage of this method is that it 
involves regrowth of tumor cells, and in several cases the 
growth of selected clones will be resistant to the therapy 
[13].  
To avoid the adverse events of bolus doses, anti-cancer 
drug can be administered in low doses over prolonged 
periods without extended rest periods which is called as 
low-dose metronomic therapy [14]. Advantages of LDM 
are its antitumor efficacy and reduced acute toxicities; 
however the major disadvantage is the empiricism 
associated with determining the optimal biologic dose 
(OBD) [15]. This is the most important problem 
oncologists are faced with when they are trying to 
translate LDM into the clinical application; however, 
according to our previous research, this can be solved by a 
closed-loop control [16].  
Low-dose daily administration of antiangiogenic drugs 
was found to be more effective than high-doses with rest 
periods. In [16], the effect of low-dose bevacizumab 
treatment on mice and human adenocarcinoma was 
examined. Article [17] makes a case for low-dose 
endostatin treatment on human lung cancer. In this 
experiment, 3 mg/kg endostatin was administered 
intravenously daily for 10 days. The results lend support 
to the view that endostatin normalizes the structure and 
function of tumor vasculature. The importance of tumor 
vasculature normalization lies on the further delivery of 
chemotherapeutic drugs. Low-dose antiangiogenic therapy 
creates the possibility of further efficient therapeutic agent 
use (if any) or assists the more effective direct antitumor 
effect of the angiogenic inhibitor [18]. 
Finally, continuous infusion therapy is applicable 
within clinical environment, but not yet as a portable 
device. However, prolonged delivery of antiangiogenic 
drugs may be carried out by mini-osmotic pumps or cell 
encapsulation systems [9, 19]. In the study [20], 
endostatin was microencapsulated into poly(lactic-co-
glycolic acid) (PLGA) microspheres to treat Lewis lung 
cancer. They found that in vivo releasing endostatin was 
biologically active and significantly inhibited the 
migration of endothelial cells. 
Several studies examined the antitumor effect of 
endostatin as a function of delivery (for instance in the 
case of pancreatic cancer [10, 21]). Continuous 
administration (using micro-osmotic pumps) was found to 
be more effective (97% inhibition of tumor growth) than 
daily bolus doses (66% inhibition of tumor growth), using 
the same dosage (20mg/kg/day).  
To sum up, there is a lot of supporting evidence from 
the medical experiments showing that low-dose 
administration of antiangiogenic drugs is more effective 
than high-dose delivery. Continuous drug administration 
may have even better efficacy; however, long-term 
continuous therapy raises technical questions which are 
not solved yet. Therefore we draw attention to the 
discrete-time control as an alternative and promising 
solution for antiangiogenic drug delivery.  
B. Simulation results of the protocol based cancer 
therapies 
We simulated the effect of the different medical 
protocols on the tumor growth model described by (1)-(3). 
The therapies were designed to be comparable; therefore 
the total administered inhibitor concentration was  
300 mg/kg in all cases. Treatment period was 15 days in 
every case. 
In the case of bolus doses with maximum tolerated dose 
(BD MTD), 100 mg/kg bolus was administered once a day 
in the 1st, 6th and 12th days of the treatment (3 times). 
The length of the drug infusion was chosen to be one 
hour. The rest periods were 5 days. 
When bolus doses (BD) were used in lower dosage,  
20 mg/kg bolus was delivered once a day every day of the 
treatment (15 times). The length of the drug infusion was 
chosen to be one hour, similarly to the BD MTD therapy. 
Consequently, the rest periods were 23 hours. 
Using low-dose metronomic regimen (LDM),  
2.5 mg/kg infusion was delivered for one day in the 1st, 
4th, 7th, 10th and 13th  days of the treatment (5 times). 
The rest periods were 2 days. 
In the case of continuous infusion therapy,  
0.8333 mg/kg/h continuous infusion was used during the 
whole treatment, without rest periods. 
Fig. 1 shows the results of the simulations. The less 
effective treatment was BD MTD, since this therapy 
reduced the tumor volume in the least amount (steady 
state tumor volume is 16330 mm3). This is consistent with 
the above mentioned clinical experimental results. In 
addition, maximum tolerated doses are not just 
therapeutically ineffective, but may cause serious adverse 
events for the patient, and therefore erode the quality of 
life.  
The effectiveness of BD and LDM therapies was 
similar. Using daily bolus doses, the steady state tumor 
volume is 15580 mm3, while low-dose metronomic 
therapy resulted in 15660 mm3 steady state tumor volume. 
Despite the similar results relating to steady state tumor 
volume, the aspect of physiological load has to be taken 
into account as well. For a long-term treatment, low-dose 
metronomic regimen can be more tolerable, and as it can 
be seen from Fig. 1, due to the smaller drug dosage, 
vascular volume changes more slowly and to a lesser 
extent in LDM therapy in contrast to BD treatment.  
The simulation results of continuous infusion therapy 
(marked as “cont” in Fig. 1) lend support to the clinical 
experimental results, since the lowest steady state tumor 
volume (15360 mm3) was achieved using this treatment. 
Other advantages of this method are the smooth change  
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Fig. 1. Protocol based therapies. Treatment period: 15 days. 
a) Bolus doses with maximum tolerated dose (BD MTD) 
Therapy: 100 mg/kg bolus once a day in the 1st, 6th and 12th days of the treatment; rest periods: 5 days. 
Total inhibitor concentration: 300 mg/kg, steady state tumor volume: 16330 mm3. 
b) Bolus doses (BD) 
Therapy: 20 mg/kg bolus once a day every day of the treatment; rest periods: 23 hours. 
Total inhibitor concentration: 300 mg/kg, steady state tumor volume: 15580 mm3. 
c) Low-dose metronomic regimen (LDM) 
Therapy: 2.5 mg/kg infusion for one day in the 1st, 4th, 7th, 10th, 13th days of the treatment; rest periods: 2 days. 
Total inhibitor concentration: 300 mg/kg, steady state tumor volume: 15660 mm3. 
d) Continuous infusion therapy (cont) 
Therapy: 0.8333 mg/kg/h continuous infusion therapy during the whole treatment; no rest periods. 
Total inhibitor concentration: 300 mg/kg, steady state tumor volume: 15360 mm3. 
 
of vascular volume during the treatment on the one hand, 
and minimal or no side effects on the other hand. 
However, we would like to emphasize once more that 
continuous long-term therapy is not yet available 
nowadays. 
IV. DISCRETE TIME CONTROLLER BASED TREATMENTS 
A. Discrete time controller with state feedback, setpoint 
control, actual state observer and load estimation 
 
Detailed description of the discrete-time controller 
design can be found in [7]. Here we give a concise 
summary of the design aspects of the discrete time 
controller with state feedback, setpoint control, actual 
state observer and load estimation. 
Taking into account that state feedback control design 
requires linear model, we applied operating point 
linearization in the g0 = 0 working point. The matrices 
of the linear model with system matrix A, input matrix B 
(i.e. the right-hand side of its differential equation is  
x = Ax + Bu), and output defined as y = Cx + Du are 
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The whole controller structure was designed for the 
linearized and discretized tumor growth model; however 
the simulations were carried out on the original nonlinear 
continuous model. 
Sampling time was chosen to fulfill the conditions of 
Shannon theorem for every signal of the accelerated 
(closed-loop) system. The continuous-time linear model 
was transformed to a discretized model that has equivalent 
step response in the sampling times, thus the difference 
equation of the discrete-time model is 
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Fig. 2. Block diagram of the discrete time control containing state feedback, setpoint control, actual state observer and load estimation. 
 
 .1 kdkdk uBxAx +=+  (7)
We investigated the observability and controllability of 
the linearized discrete model, and we found that the 
matrices are full rank for every nonzero operating point, 
thus the system is controllable and observable. 
State feedback control problem was solved by two 
different control methods. In the case of pole placement, 
the feedback matrix K was determined by the 
Ackermann’s formula, i.e. 
),(),(1 dclosedddC
T
nPP ABAMeK ϕ
−
=  (8) 
where en is the nth unit vector, φclosed(Ad) is the 
characteristic polynomial of the closed loop evaluated at 
the matrix Ad and Mc is the controllability matrix 
evaluated as  
 ( ).),( 1 dnddddddC BABABBAM −=   (9)
     The feedback matrix K was also calculated for the 
discrete time LQ problem using the formula 
( ) ,1 dTddTdLQ PABPBBRK −+=  (10) 
where P is the solution of the Discrete-time Algebraic 
Ricatti Equation (DARE) 
( )( ) ( ) QPABPBBRPBAPAAP dTddTddTddTd ++−= −1 (11)
where .CCQ T=  
For setpoint control, two matrices (Nx and Nu) are 
needed to extend the control structure (provided that the 
reference signal is piecewise continuous):    
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Actual state observer was designed to estimate the non-
measurable state variables. It is described by the 
difference equation 
,ˆˆ 11 −− ++= iiii HuGyxFx  (13) 
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( ) ( )( ) ,,e 1Tn TTdFTdTdTdc
dd
dd
ACAAMG
GCBBH
GCAAF
ϕ−=
−=
−=
 
(14)
(15) 
(16) 
where φF(AdT) refers to the characteristic polynomial of 
the matrix F evaluated at the matrix AdT. 
We also designed load estimation; we assumed that the 
disturbance is reduced to the input of the system (load 
change) and it is piecewise constant, so the discrete-time 
model was extended by the load modeled as a constant 
state-variable that adds up to the input of the original 
model. 
The state feedback and the setpoint control was 
designed for the original system; however, the actual state 
observer was designed for the extended system, whose 
difference equation is 
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Fig. 2 shows the whole closed-loop control system 
containing the controller and the nonlinear system. We 
placed saturation between the tumor model and the 
controller; in addition, control input has a lower and 
an upper limit due to physiological considerations. 
B. Simulation results of the discrete-time controller 
based treatments 
Discrete controller based therapies are automatic 
treatments which can contain bolus doses and metronomic 
periods as inputs. The whole treatment periods are the 
same as in protocol based cancer therapies, i.e. 15 days. 
Each discrete controller has the following parameters 
(which were chosen according to [7]). The operating 
point, where the original nonlinear system was linearized, 
is 10 mm3. Controllers use LQ optimal control as a state 
feedback method. The value of R weighting matrix is 1. 
The reference signal is 13000 mm3 to get steady state 
tumor volume results close to the protocol based cancer 
therapies’ values. The disturbance was chosen to be 0%, 
since protocol based cancer therapies do not have 
disturbance either in the simulations. The controllers differ 
only in the chosen saturation level. 
Fig. 3 shows the results of the simulations. Using the 
maximum tolerated dose as the saturation level (100 
mg/kg, note that this is the same value as it was at the 
protocol based therapies’ BD MTD case), there are more 
than one rest periods, and these periods are not located at 
equal intervals. The therapy begins with a maximum bolus 
dose, and after that, a half day rest period follows. The 
next phase takes 3 days; during this period, maximum 
bolus doses follow each other in about 5-10 hours. After 
that an approximately 6.5-day rest period follows. This  
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Fig. 3. Discrete controller based therapies. Treatment period: 15 days.  
Parameters: operating point: 10 mm3; R: 1; reference signal: 13000 mm3; disturbance: 0%. 
a) Saturation: 100 mg/kg 
Total inhibitor concentration: 138 mg/kg, steady state tumor volume: 9870 mm3. 
b) Saturation: 20 mg/kg 
Total inhibitor concentration: 56 mg/kg, steady state tumor volume: 11360 mm3. 
c) Saturation: 2.5 mg/kg 
Total inhibitor concentration: 30 mg/kg, steady state tumor volume: 13153 mm3. 
 
 
ends with a 10 mg/kg bolus dose; and then a 2-day period 
occurs again with maximum bolus doses following each 
other in about 5-10 hours. The therapy ends with a 2.5-day 
rest period. The total inhibitor concentration is 138 mg/kg, 
and the achieved steady state tumor volume is 9870 mm3. 
As it can be seen from Fig. 3, at the end of the 15th day, 
the output value shows an undershoot; this is the 
explanation of the great difference from the setpoint. 
In the second case, the saturation was chosen to be 
20 mg/kg (similarly to the protocol based therapies’ BD 
case). This treatment also has three rest periods; however, 
these rest periods are shorter compared to the maximum 
tolerated dose saturation case. In turn, the characteristics 
of the treatments are really similar: after the very first 
bolus dose, the shortest rest period occurs first, which is 
followed by the longest bolus dose period, and then the 
longest rest period appears, which is followed by a shorter 
bolus dose period, and finally, the second longest rest 
period comes. The bolus doses are not equal to the 
saturation value in every case (there are lower boluses). 
The total inhibitor concentration is 56 mg/kg, and the 
gained steady state tumor volume is 11360 mm3. Since the 
input boluses (and hence the over-and undershoots) are 
not as high as the MTD, the steady state tumor volume 
approximates the setpoint better. 
The third discrete controller has 2.5 mg/kg saturation 
limit (which is the same value as it was at the protocol 
based therapies’ LDM case). Having regard to the low 
possible value of the input, to reach the setpoint, the 
control contains only one short rest period at the 
beginning of the treatment (approximately half a day). 
After that a 7.5-day prolonged period comes where the 
input keeps the value of saturation. The treatment ends 
with a 6.5-day long period where maximum bolus doses 
follow each other in about 5 hours. The total inhibitor 
concentration during the treatment is 30 mg/kg, and the 
achieved steady state tumor volume is 13153 mm3. 
V. RESULTS AND DISCUSSION 
Comparison of the therapies as a function of total 
inhibitor concentration and steady state tumor volume can 
be seen in Fig. 4. 
Since the protocol based therapies were designed to be 
comparable (the total administered inhibitor concentration 
was 300 mg/kg in all cases), the efficacy order can be 
easily set up. Bolus doses therapy with maximum 
tolerated dose (BD MTD) is the less effective in terms of 
tumor volume reduction. Bolus doses therapy with lower 
dose (BD) and low-dose metronomic regimen (LDM) has 
similar results, and continuous infusion therapy reduces 
the tumor volume in the greatest extent.  
However, it is trivial from Fig. 4, that even the best 
protocol based therapy cannot approach the effectiveness 
of discrete controller based therapies, since these 
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Fig. 4. Comparison of the therapies as a function of total inhibitor 
concentration and steady state tumor volume. Protocol based therapies: 
bolus doses with maximum tolerated dose (BD MTD), bolus doses (BD), 
low-dose metronomic regimen (LDM), continuous infusion therapy 
(cont). Discrete controller based therapies: saturation: 100 mg/kg (sat = 
100), saturation: 20 mg/kg (sat = 20), saturation: 2.5 mg/kg (sat = 2.5). 
 
automated treatments achieve considerably lower steady 
state tumor volumes while using less than half total 
inhibitor concentration. The choice between the automated 
treatments depends on the current therapeutic goal. If the 
goal is to reduce the tumor volume as fast as possible, and 
the patient tolerates MTD boluses, the 100 mg/kg 
saturation is the most appropriate way. The  
20 mg/kg saturation level is a trade-off choice: the 
physiological load of the patient is less; however, the 
gained steady state tumor volume is higher compared to 
the BD MTD therapy. Taking into account the above 
mentioned vasculature normalization aspect and the 
minimal side effects; 2.5 mg/kg saturation seems to be the 
best therapeutic choice in most cases. 
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